Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Robert J MotzerSaby GeorgeJaime R MerchanThomas E HutsonXun SongRodolfo F PeriniRan XieUrmi BapatJavier PuentePublished in: The oncologist (2023)
NCT02811861.